ReviewNature reviews. Clinical oncology2010
Ovarian cancer: the duplicity of CA125 measurement.
Review in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 93 citations in OpenAlex.
- Extracellular Vesicle Protein Panel Enables Early Lung Cancer Detection in a Large Clinical Cohort.Journal of extracellular vesicles · 2025Trial
- Early and accurate detection of ovarian cancer by profiling cell-free mitochondrial DNA fragmentomics in multi-ethnic population.Genome medicine · 2026Article
- Large scale evaluation of a multiple tumor marker panel for lung cancer diagnosis and histological subtyping.Discover oncology · 2026Article
- Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors.Molecular and clinical oncology · 2026Article
- Selenium-Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- MRI-Based Classification Systems Combined with Serum CA125 for Predicting Symptom Recurrence After Ultrasound-Guided High-Intensity Focused Ultrasound Ablation Surgery for Adenomyosis: A Retrospective Cohort Study.International journal of women's health · 2026Article
- Nanopore-based enzyme-linked immunosorbent assay for cancer biomarker detection.Nature nanotechnology · 2025Article
- Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis.Cancer innovation · 2025Article
- Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression.Nature communications · 2025Article
- On the Quest for Biomarkers: A Comprehensive Analysis of Modified Nucleosides in Ovarian Cancer Cell Lines.Cells · 2025Article
- The role of chloride intracellular channel 4 in tumors.Cancer cell international · 2025Review
- Machine learning-derived diagnostic model of epithelial ovarian cancer based on gut microbiome signatures.Journal of translational medicine · 2025Article
- Prognostic value of CA125 in diffuse large B-cell lymphoma.Frontiers in oncology · 2025Article
- Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer.Journal of ovarian research · 2024Article
- Noninvasive serum N-glycans associated with ovarian cancer diagnosis and precancerous lesion prediction.Journal of ovarian research · 2024Article
- Four-protein model for predicting prognostic risk of lung cancer.Frontiers of medicine · 2022Article
- Lectin affinity-based glycoproteome analysis of the developing xylem in poplar.Forestry research · 2022Article
- Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer.Materials today. Bio · 2022Article
- Colon carcinoma presenting as ovarian metastasis.Radiology case reports · 2021Article
- A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since it was first described in 1981, CA125 has held an important role in monitoring patients with ovarian cancer. CA125 is elevated in 80% of patients with epithelial ovarian cancer at initial diagnosis and correlates well with response to therapy. CA125 monitoring is used for the follow up of patients with epithelial ovarian cancer, and elevations in CA125 measurements often antedate any signs, symptoms or radiographic evidence of disease by several months. Unfortunately, data favoring early therapeutic intervention for recurrent ovarian cancer is lacking, especially in patients with isolated CA125 elevations. In asymptomatic patients, elevations in CA125 have been associated with considerable anxiety and deterioration in quality of life without any significant gains in survival. Patients with ovarian cancer should, therefore, be counseled regarding the advantages and shortcomings of intensive CA125 testing. While some patients may benefit from early detection of recurrent disease and be candidates for secondary cytoreductive surgery, others may choose to delay therapy until they develop symptoms of disease recurrence. The results of a clinical trial suggest that withholding treatment in the event of isolated rising CA125 levels will not negatively impact these patients overall survival, highlighting the need for improved salvage therapies for recurrent ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.